Med Lett Drugs Ther. 2005 Feb 28;47(1203):19-20.
Abacavir/lamivudine (Epzicom) and emtricitabine/tenofovir (Truvada), two new once-daily fixed-dose NRTI combinations, have been approved for use in antiretroviral regimens to treat HIV infection. Epzicom appears to be as effective as its components taken separately and, in one study, Truvada was at least as effective as zidovudine/lamivudine (Combivir). Use of once-daily fixed-dose combinations means less flexibility in dosing, and some patients with hepatic or renal impairment will not be able to take them.
阿巴卡韦/拉米夫定（依非韦伦）和恩曲他滨/替诺福韦（特鲁瓦达）是两种新型的每日一次固定剂量核苷类逆转录酶抑制剂组合药物，已被批准用于抗逆转录病毒治疗方案以治疗HIV感染。依非韦伦似乎与其单独使用的成分效果相同，并且在一项研究中，特鲁瓦达至少与齐多夫定/拉米夫定（双汰芝）效果相当。每日一次固定剂量组合药物的使用意味着给药灵活性降低，一些肝肾功能不全的患者将无法使用。
